These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

100 related articles for article (PubMed ID: 11163560)

  • 1. Neurological and general outcome in low-risk coronary artery bypass patients using heparin coated circuits.
    Svenmarker S; Sandström E; Karlsson T; Häggmark S; Jansson E; Appelblad M; Lindholm R; Aberg T
    Eur J Cardiothorac Surg; 2001 Jan; 19(1):47-53. PubMed ID: 11163560
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Comparison of two heparin-coated extracorporeal circuits with reduced systemic anticoagulation in routine coronary artery bypass operations.
    Ovrum E; Tangen G; Oystese R; Ringdal MA; Istad R
    J Thorac Cardiovasc Surg; 2001 Feb; 121(2):324-30. PubMed ID: 11174738
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Heparin-coated circuits (Duraflo II) with reduced versus full anticoagulation during coronary artery bypass surgery.
    Ovrum E; Tangen G; Oystese R; Ringdal MA; Istad R
    J Card Surg; 2003; 18(2):140-6. PubMed ID: 12757341
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Clinical effects of the heparin coated surface in cardiopulmonary bypass.
    Svenmarker S; Sandström E; Karlsson T; Jansson E; Häggmark S; Lindholm R; Appelblad M; Aberg T
    Eur J Cardiothorac Surg; 1997 May; 11(5):957-64. PubMed ID: 9196315
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Effects of two differently heparin-coated extracorporeal circuits on markers for brain and myocardial dysfunction.
    Flom-Halvorsen HI; Ovrum E; Brosstad F; Tangen G; Ringdal M; Oystese R
    Perfusion; 2002 Sep; 17(5):339-45. PubMed ID: 12243437
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Synthetic protein treated versus heparin coated cardiopulmonary bypass surfaces: similar clinical results and minor biochemical differences.
    Wimmer-Greinecker G; Matheis G; Martens S; Oremek G; Abdel-Rahman U; Moritz A
    Eur J Cardiothorac Surg; 1999 Aug; 16(2):211-7. PubMed ID: 10485423
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Use of heparin-bonded circuits in cardiopulmonary bypass improves clinical outcome.
    Svenmarker S; Häggmark S; Jansson E; Lindholm R; Appelblad M; Sandström E; Aberg T
    Scand Cardiovasc J; 2002 Aug; 36(4):241-6. PubMed ID: 12201973
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Duraflo II coating of cardiopulmonary bypass circuits reduces complement activation, but does not affect the release of granulocyte enzymes : a European multicentre study.
    Fosse E; Thelin S; Svennevig JL; Jansen P; Mollnes TE; Hack E; Venge P; Moen O; Brockmeier V; Dregelid E; Haldén E; Hagman L; Videm V; Pedersen T; Mohr B
    Eur J Cardiothorac Surg; 1997 Feb; 11(2):320-7. PubMed ID: 9080162
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Effects of Duraflo II heparin-coated cardiopulmonary bypass circuits on the coagulation system, endothelial damage, and cytokine release in patients with cardiac operation employing aprotinin and steroids.
    Inui K; Shimazaki Y; Watanabe T; Takahashi T; Minowa T; Takeda H; Yanagawa N; Sotoda Y
    Artif Organs; 1999 Dec; 23(12):1107-12. PubMed ID: 10619929
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Heparinized cardiopulmonary bypass and full heparin dose marginally improve clinical performance.
    Ovrum E; Am Holen E; Tangen G; Ringdal MA
    Ann Thorac Surg; 1996 Oct; 62(4):1128-33. PubMed ID: 8823101
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Complement and granulocyte activation in two different types of heparinized extracorporeal circuits.
    Ovrum E; Mollnes TE; Fosse E; Holen EA; Tangen G; Abdelnoor M; Ringdal MA; Oystese R; Venge P
    J Thorac Cardiovasc Surg; 1995 Dec; 110(6):1623-32. PubMed ID: 8523872
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Biocompatibility of heparin-coated extracorporeal bypass circuits: a randomized, masked clinical trial.
    Muehrcke DD; McCarthy PM; Kottke-Marchant K; Harasaki H; Pierre-Yared J; Borsh JA; Ogella DA; Cosgrove DM
    J Thorac Cardiovasc Surg; 1996 Aug; 112(2):472-83. PubMed ID: 8751516
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Coronary artery bypass surgery with heparin-coated perfusion circuits and low-dose heparinization.
    Mullen JC; Bentley MJ; Gelfand ET; Koshal A; Modry DL; Guenther CR; Etches WS; Stang LJ; Lopushinsky SR
    Can J Surg; 2002 Jun; 45(3):166-72. PubMed ID: 12067167
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Heparin-coated cardiopulmonary bypass circuits and 25% reduction of heparin dose in coronary artery surgery--a clinical study.
    Borowiec J; Thelin S; Bagge L; van der Linden J; Thörnö E; Hansson HE
    Ups J Med Sci; 1992; 97(1):55-66. PubMed ID: 1523735
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Biocompatibility of heparin-coated cardiopulmonary bypass circuits in coronary patients with left ventricular dysfunction is superior to PMEA-coated circuits.
    Kutay V; Noyan T; Ozcan S; Melek Y; Ekim H; Yakut C
    J Card Surg; 2006; 21(6):572-7. PubMed ID: 17073955
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Endothelin-1 and neutrophil activation during heparin-coated cardiopulmonary bypass.
    Lundblad R; Moen O; Fosse E
    Ann Thorac Surg; 1997 May; 63(5):1361-7. PubMed ID: 9146328
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A prospective randomized trial of Duraflo II heparin-coated circuits in cardiac reoperations.
    McCarthy PM; Yared JP; Foster RC; Ogella DA; Borsh JA; Cosgrove DM
    Ann Thorac Surg; 1999 May; 67(5):1268-73. PubMed ID: 10355394
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Disparity in blood activation by two different heparin-coated cardiopulmonary bypass systems.
    Moen O; Fosse E; Brockmeier V; Andersson C; Mollnes TE; Høgåsen K; Venge P
    Ann Thorac Surg; 1995 Nov; 60(5):1317-23. PubMed ID: 8526620
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Heparin coating of an extracorporeal circuit partly improves hemostasis after cardiopulmonary bypass.
    Boonstra PW; Gu YJ; Akkerman C; Haan J; Huyzen R; van Oeveren W
    J Thorac Cardiovasc Surg; 1994 Jan; 107(1):289-92. PubMed ID: 8283898
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Heparin-coated bypass circuits (Carmeda) suppress the release of tissue plasminogen activator during normothermic coronary artery bypass graft surgery.
    Spiess BD; Vocelka C; Cochran RP; Soltow L; Chandler WL
    J Cardiothorac Vasc Anesth; 1998 Jun; 12(3):299-304. PubMed ID: 9636912
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.